Wang Jing, Li Ran, Wang Qianqian, Chen Yongfeng, Gao Tingyi, Han Rui, Li Nan, Zhang Kai
Department of Stomatology, The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, P. R. China.
Department of Pathology, The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, P. R. China.
Int J Clin Exp Pathol. 2020 Aug 1;13(8):2050-2057. eCollection 2020.
Lymphoma of the parotid gland is a rare malignant tumor, and cohort studies on the survival rates of affected patients are sparse. This study aimed to retrospectively evaluate the clinicopathological characteristics of patients diagnosed with non-Hodgkin lymphoma of the parotid gland. This study included 31 patients diagnosed with lymphoma of the parotid gland. Data on the pathological subtypes, the WHO classifications of the hematopoietic and lymphoid tissues, and the Ann Arbor staging, treatment modalities, and survival times were collected and analyzed. Among the 31 patients, there were 18 cases of extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT), 7 cases of diffuse large B-cell lymphoma (DLBCL), and 6 cases of follicular lymphoma (FL). The tumors were most-commonly located in the superficial lobe of the parotid gland (28/31), and three cases involved the deep lobe of the parotid gland (3/31). The overall median survival from the diagnosis of lymphoma was estimated to be 62 months, with 3-year and 5-year survival rates of 83.9% and 77.4%, respectively. A univariate analysis demonstrated statistically significant differences in accelerated tumor growth (P<0.001) and the presence of tumor capsules (P<0.001). A multivariate analysis demonstrated statistically significant differences in the accelerated tumor growth (P=0.029). MALT lymphoma was the most common subtype of primary parotid lymphoma. The prognosis is better than it is with other malignant parotid tumors. The presence of accelerated tumor growth was significantly correlated with overall survival time.
腮腺淋巴瘤是一种罕见的恶性肿瘤,关于患病患者生存率的队列研究较少。本研究旨在回顾性评估被诊断为腮腺非霍奇金淋巴瘤患者的临床病理特征。本研究纳入了31例被诊断为腮腺淋巴瘤的患者。收集并分析了病理亚型、造血与淋巴组织的WHO分类、Ann Arbor分期、治疗方式及生存时间的数据。31例患者中,有18例黏膜相关淋巴组织边缘区B细胞淋巴瘤(MALT)、7例弥漫性大B细胞淋巴瘤(DLBCL)和6例滤泡性淋巴瘤(FL)。肿瘤最常位于腮腺浅叶(28/31),3例累及腮腺深叶(3/31)。淋巴瘤诊断后的总体中位生存期估计为62个月,3年和5年生存率分别为83.9%和77.4%。单因素分析显示肿瘤生长加速(P<0.001)和肿瘤包膜的存在(P<0.001)有统计学显著差异。多因素分析显示肿瘤生长加速有统计学显著差异(P=0.029)。MALT淋巴瘤是原发性腮腺淋巴瘤最常见的亚型。其预后优于其他腮腺恶性肿瘤。肿瘤生长加速与总生存时间显著相关。